设为首页|加入收藏|英文版

总体介绍

首页 > 广东省中医药科学院 > 总体介绍

中医药防治病毒性肝炎临床研究团队

2017/7/6 15:27:43字号:T|T

 

中医药防治病毒性肝炎临床研究团队是在中医基础理论的指导下,围绕多维立体系列疗法体系,针对慢性病毒性肝炎的临床证治规律变化,运用中医、中西医结合、内外科结合治疗慢性病毒性肝炎,拥有国家中医药管理局“中医肝病免疫实验室”,将慢性病毒性肝炎的临床研究与基础研究相结合,提高临床疗效。

The Team of TCM Treatment of Viral hepatitis focus on the change of viral hepatitis TCM syndrome under the guidance of the basic theory of TCM. With the integration of Chinese and western medicine therapy theory, we proceed to the clinical and basic research of viral hepatitis. We have the key laboratory of Immune Laboratory of TCM from the state administration of traditional Chinese medicine.

 

团队主攻方向Main direction

1. 中医药干预慢性病毒性肝炎相关肝纤维化临床研究

主要开展多维立体系列疗法体系预防与治疗慢性病毒性肝炎相关肝纤维化的临床研究,临床研究表明,无论是轻症肝纤维化(S≤2还是显著肝纤维化(S≥2),运用疏肝健脾和血通络法能够提高肝纤维化逆转率,降低肝纤维化进展率,阻断慢性病毒性肝炎疾病进展。

 

1. Blocking liver fibrosis in chronic viral hepatitis patients treated by Traditional Chinese Medicine

We mainly focus on the study of multi dimensional series therapy system in treating chronic viral hepatitis patients with liver fibrosis. The results of our clinical study tells us that the therap of Soothing Liver and Strengthening Spleen and Activating Blood could reverse hepatitis B-related liver fibrosis.,decrease the progress of hepatic fibrosis, and block the progress of chronic viral hepatitis,Whether it is mild liver fibrosis S2 or significant fibrosis S2

 

2.中医药提高慢性病毒性肝炎抗病毒疗效的临床研究

开展中西医结合治疗提高慢性病毒性肝炎HBeAg血清转换率、降低病毒耐药率以及减少停药复发率的临床研究,采用中西医结合治疗的方法,拉米夫定治疗1年(52周)YMDD变异率仅6.82%,恩替卡韦治疗48周的HBeAg血清转换率为34.2%,处于全国领先水平。

2 Improving the antiviral effect in chronic viral hepatitis patients with traditional Chinese medicine

We conduct clinical studies on the combination of traditional Chinese medicine and Western medicine treatment to improve the HBeAg serum conversion rate, reduce the virus resistance rate and reduce the recurrence rate of the drug in chronic viral hepatitis patients. The results showed us that YMDD mutation rate was only 6.82% in patients treated with lamivudine and TCM in 52 weeks and the HBeAg serum conversion rate was 34.2% in patients treated with entecavir for 48 weeks, which was at the national leading level.

 

3.中医药干预慢性病毒性肝炎全程管理的研究

主要针对慢性病毒性肝炎的全程管理,运用中医药干预,提高患者的依从性,从早期、全程、分层次、分阶段全程管理慢性病毒性肝炎,包括乙型肝炎、丙型肝炎、肝纤维化、肝硬化等,早期发现患者发生肝硬化及HCC的风险,并采用中医药早期干预,减少肝硬化、HCC的发生率。

 3. Study on the whole process management of chronic viral hepatitis treated with Traditional Chinese medicine

We focus on the whole process management of chronic viral hepatitis treated with TCM. To conduct the whole process management of chronic viral hepatitis patients with TCM,from the early stage and different level and stage,Including hepatitis B, hepatitis C, liver fibrosis, cirrhosis, etc.So we also could detect the patients with high risk of cirrhosis and HCC early. And we could reduce the incidence of cirrhosis and HCC with TCM at early stage.


学术带头人Academic leaders

Professor Xiaoling Chi, chief physician, the famous doctor in TCM of Guangdong province, the vice president of China Branch Institute of national medicine liver disease, the vice president of Chinese Institute of national medicine infectious disease branch, the deputy Secretary of China traditional Chinese Medicine Society of liver disease professional committee, the director of the expert committee of the Guangdong province for the use of Chinese medicine in the treatment of liver diseases.She has presided over 1 sub subject of the national "Twelfth Five Year" major infectious disease science and technology special issue, 1 issue of the national health and Family Planning Commission, participating in 9 issues of the national "eleven five", " Twelfth Five Year Plan" major infectious diseases of major science and technology projects, won 1 award of the Chinese medical science, get 3 invention patents, won 1 award of provincial science and technology achievement, obtain 1 issue of bureau level achievement award.

池晓玲:主任医师,广东省名中医,中国民族医药学会肝病分会副会长,中国民族医药学会传染病分会副会长,中华中医药学会肝病专业委员会副秘书长,广东省药学会中医肝病用药专家委员会主任委员,主持国家“十二五”重大传染病科技专项课题子课题1项,国家卫生计生委课题1项,参与国家“十一五”、“十二五”重大传染病科技重大专项课题9项,获华夏医学科普奖1项,发明专利3项,获省级科技成果奖1项,获得厅局级成果奖1项。

承担的主要研究课题

课题名称

任务来源

级别

负责人

经费

(万元)

国家“十二五”重大传染病专项子课题“中医药逆转乙型肝炎相关肝纤维化临床效果的评价研究”

国家卫生部

国家级

池晓玲

304.14

恩曲他滨治疗慢性乙肝初治患者上市后临床研究

国家卫生计生委

国家级

池晓玲

5

慢性病毒性肝炎中西医结合治疗方案优化研究

国家卫生部

国家级

池晓玲

29

中医药缩短自身免疫性肝炎激素使用疗程的疗效评价研究

广东省财政厅

省级

池晓玲

30

补肾祛邪法治疗慢性乙型肝炎临床研究

国家中医药管理局

部级

池晓玲

21

疏肝健脾方干预肝郁脾虚型肝纤维化大鼠模型p38 MAPK信号通路的研究

广东省自然基金

省级

萧焕明

10

慢性乙型病毒性肝炎(HBeAg阴性)患者中西医结合治疗方案优化研究

国家卫生部

国家级

田广俊

16.65

慢性乙肝病毒携带者中医综合干预方案研究

国家卫生部

国家级

蒋俊民

15

ASC体质分布特点及其与HBV DNA定量、B淋巴细胞计数、FS值的相关性研究

广东省科技厅

省级

田广俊

 

 

取得的成果专利

专利

时间

人员

排名

一种治疗腹胀的敷脐药物及其制备方法”(ZL 200710028055.3

2007

池晓玲

1

一种治疗病毒性肝炎黄疸的中药外用药物及其制备方法(ZL 200810028898.8

2008

池晓玲

1

一种治疗肝硬化腹水的中药外用药物及其制备方法(ZL 200810028899.2

2008

池晓玲

1

 




 

首页|网站地图|法律申明|友情链接|招聘信息|供应商管理|名老中医学术交流|中医健康管理|中医医案管理 |知识管理|在线考试